We are pleased to invite current and prospective investors to join BioVaxys Technology Corp. at the 2021 GCFF Virtual Healthcare Investment Conference, Thursday June 10, 2021 8am – 1pm PST (11am – 4pm EST). As part of the conference, BioVaxys CEO James C. Passin will be presenting the company’s product development portfolio and clinical plans.
Based in Vancouver, BioVaxys Technology Corp., a British Columbia-registered clinical-stage biotechnology company, is developing viral and oncology vaccines based on its proprietary hapten-conjugated antigen platforms, as well as immuno-diagnostic products. BioVaxys common shares trade on the CSE under the stock symbol “BIOV” and are listed on the Frankfurt Bourse (FRA: 5LB) and the OTCQB Venture Market (OTCQB: BVAXF).
The Company is preparing for a Phase I clinical study in Spain of BVX-0918A, its cancer vaccine in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors, in late-stage ovarian cancer. The 1Q2022 study is being conducted via a joint clinical development and marketing collaboration with our Spanish pharma partner, Procare Health Iberia (Barcelona). The haptenized cancer vaccine platform is scalable to other solid and liquid tumors, and BioVaxys is evaluating vaccines for cervical cancer, melanoma, renal cell carcinoma, uterine cancer, NSCLC, and other tumor types.
Register now and tune in to the presentation at
8:30 am – 8:50 am PST (11:30 am – 11:50 am EST)
Thursday June 10, 2021
8am – 1pm PST (11am – 4pm EST)
In 2020, BioVaxys completed preclinical development of BVX-0320, its haptenized recombinant SARS-CoV-2 s-protein vaccine, and is now looking now to file a CTA to conduct a Phase I study in Canada. In addition to an emerging safe and well-tolerated profile, BVX-0320 elicited a 96.4% positive antibody response and activated CD4+ helper T cells and CD8+ killer T cells that express the activation markers, CD69 and CD25, with the test animals developing splenic T cells that produced the type I cytokine, gamma interferon, and development of neutralizing antibodies. The haptenized viral antigen platform can be expanded to address other viruses, such as CoV1, Zika, etc., and BioVaxys is evaluating the potential for a HPV vaccine.
These BioVaxys vaccine platforms are based on the established immunological concept that modifying cell surface proteins—whether they are viral or tumor—with a chemical known as a “hapten” significantly increases the ability of the immune system to recognize and react to those cells. This process of haptenization “teaches” a patient’s immune system to recognize and make target proteins more ‘visible’ as foreign, thereby stimulating a T-cell mediated immune response. This is critical for fighting viral pathogens or cancer cells, as T-cells directly battle viruses or tumors by targeting and destroying infected (or cancerous) cells.
Also in the pipeline is CoviDTH®, the worlds first low cost, disposable, point-of-care diagnostic tool that screens for a T-cell response to SARS-CoV-2 in vaccinated patients, or those exposed to SARS-CoV-2. The Company has submitted to the US FDA a Phase III pre-IND briefing, and plans to submit a Canadian CTA later this year to conduct a pivotal study for marketing approval.
BioVaxys has right of refusal to market Papilocare® in the US, which is Procare Health Iberia’s topical gel for treating HPV-associated cervical lesions. Papilocare is currently approved and sold in the EU as a device, with an FDA review pending. We are very excited with the revenue generating prospects for this unique, first-in-market product.
We are looking forward to sharing our presentation with you.